A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The ...

Gastric cancer cells can activate KRAS-driven signals, enabling autonomous tumor growth by producing their own WNT proteins. New research reveals how gastric cancer cells exploit WNT signaling for ...

Recent research from the University of Helsinki sheds new light on the behavior of the KRAS gene in two of the deadliest cancers—pancreatic and colorectal cancer. These findings suggest potential ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

BOSTON & SEATTLE--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical ...

A team of scientists has successfully developed a groundbreaking targeted therapy that hones in on the KRAS protein that drives some of the deadliest human cancers, including pancreatic, lung and ...

Mutations of the KRAS gene are commonly known to lead to cancer. However, deeper understanding of exactly how they do this continues to be explored by cancer researchers. Scientists at The University ...

Sotorasib conferred durable clinical benefit among previously treated patients with KRAS p.G12C-mutated non-small cell lung cancer, according to results of the phase 2 CodeBreaK 100 trial presented ...

Assistant Professor of Biomolecular Engineering Daniel Kim. A key genetic mutation that occurs early on in cancer alters RNA “dark matter” and causes the release of previously unknown RNA biomarkers ...

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now, UC San Francisco researchers ...